Nov 12, 2018
News
At NGM, we pride ourselves on conducting world-class science and sharing our research efforts with the broader scientific and medical communities.
Nov 09, 2018
NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH
Nov 06, 2018
NGM Bio Announces Multiple Presentations at AASLD’s The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313
Oct 01, 2018
NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer
Apr 14, 2018
NGM Bio Announces Results From Phase 2 Study Of NGM282 In Nash Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks
Apr 13, 2018
NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis
Mar 12, 2018
NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018
Feb 05, 2018